Research Library / GH Axis / Ipamorelin
GH Axis researchIpamorelin
NNC 26-0161 · GH secretagogue
A relatively selective GH secretagogue investigated in limited human pharmacology and postoperative settings. The listed community example (assessment · week 1) describes 100 mcg per administration, once daily, via subcutaneous; this is not a validated dosing recommendation. An illustrative 10 mg vial at an assumed 2 mL final volume yields 5 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 10mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 5mg/mL · conditional arithmetic
- One U-100 marking
- 50mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
0.03 mg/kg · intravenous · twice daily · postoperative days 1–7 or hospital discharge
Adults following bowel resectionInt J Colorectal Dis, 2014Single 15-minute intravenous infusion across 4.21–140.45 nmol/kg study levels; terminal half-life approximately 2 hours, not a subcutaneous dosing interval
Healthy male volunteersPharm Res, 1999No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryFDA safety-risk resourceReported schedule context
- Range
- 100–300 mcg/day in the staged example
- Frequency
- Once daily or divided into two administrations
- Route
- Subcutaneous
- Reported half-life
- ~2 hours after IV infusion in healthy volunteers
- Reported cycle
- 8–12 weeks on; 4 weeks off commonly reported
The staged table uses a daily total, not that amount at every administration. Fasting, subcutaneous timing and an off-cycle are community conventions, not validated by the IV study.
Cross-reference reviewed October 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Assessment · Week 1 | 100 mcg | 100 mcg/day | Once daily | Bedtime, fasted | Subcutaneous | Community-reported |
| Titration · Weeks 2–3 | 100–200 mcg | 200 mcg/day | Once daily or divided | Bedtime or morning fasted plus bedtime | Subcutaneous | Community-reported |
| Standard · Weeks 4–8 | 100–300 mcg | 200–300 mcg/day | Once or twice daily | Morning fasted and/or bedtime | Subcutaneous | Community-reported |
| Extended · Weeks 9–12 | 100–300 mcg | 200–300 mcg/day | Once or twice daily | Continue the established timing pattern | Subcutaneous | Community-reported |
| Off-cycle · 4 weeks | 0 mcg | 0 mcg/day | No administrations | Reported resting period | Not applicable | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
50 example portions per vial
50 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
200 mcg · 5 mg/mL · 0.04 mL · 4 units
FDA distinguishes ipamorelin free base from acetate and notes limited free-base water solubility and sensitivity to formulation conditions. The 10 mg/2 mL arithmetic is not verified solubility for every form. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
10 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific · Assessment · Week 1
Vial counts and final solution totals below use the selected 10 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 100 mcg | Once daily | 0.7 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 2.8 mg | 1 × 10 mg |
| 8 weeks | 5.6 mg | 1 × 10 mg |
| 12 weeks | 8.4 mg | 1 × 10 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 2 mL | Not established |
| 8 weeks | 2 mL | Not established |
| 12 weeks | 2 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 28 |
| 8 weeks | 56 |
| 12 weeks | 84 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 100 administrations
8 weeks: 100 administrations
12 weeks: 100 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Ipamorelin · NNC 26-0161 · GH secretagogue
- Evidence / status
- Early human. Investigational — not FDA approved
- Clinical route, frequency & duration
Postoperative ileus trial: 0.03 mg/kg · intravenous · twice daily · postoperative days 1–7 or hospital discharge
Human IV pharmacokinetics: Single 15-minute intravenous infusion across 4.21–140.45 nmol/kg study levels; terminal half-life approximately 2 hours, not a subcutaneous dosing interval
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- GH release, sleep or recovery, and body-composition support, often chosen for perceived selectivity.
- Reported timing / route
- Once daily or divided into two administrations · Subcutaneous. Schedule-specific timing remains in the Community tab.
- Reported half-life
- ~2 hours after IV infusion in healthy volunteers · community-reference context, not a shelf life.
- Reported cycle
- 8–12 weeks on; 4 weeks off commonly reported. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
FDA distinguishes ipamorelin free base from acetate and notes limited free-base water solubility and sensitivity to formulation conditions. The 10 mg/2 mL arithmetic is not verified solubility for every form.
Other vehicles and approaches discussed
Vendor water/acid accounts and clouding reports are separate from regulator findings. No universal acid, PBS or BAC-water method is established for every vial.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Salt-dependent solubility / aggregation concern
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Salt-dependent solubility / aggregation concern
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Ghrelin receptor agonist / growth hormone secretagogue
A relatively selective GH secretagogue investigated in limited human pharmacology and postoperative settings.
Community-reported purpose
GH release, sleep or recovery, and body-composition support, often chosen for perceived selectivity.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Postoperative ileus trial
Protocol: 0.03 mg/kg · intravenous · twice daily · postoperative days 1–7 or hospital discharge
Population: Adults following bowel resection
Read the cited evidenceHuman IV pharmacokinetics
Protocol: Single 15-minute intravenous infusion across 4.21–140.45 nmol/kg study levels; terminal half-life approximately 2 hours, not a subcutaneous dosing interval
Population: Healthy male volunteers
Read the cited evidenceEvidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
The postoperative trial did not show significant efficacy versus placebo. It does not establish chronic or subcutaneous use. FDA flags immunogenicity from aggregation/impurities and insufficient safety information for other injectable routes.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Ipamorelin?
A relatively selective GH secretagogue investigated in limited human pharmacology and postoperative settings.
Ghrelin receptor agonist / growth hormone secretagogue
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
8–12 weeks on; 4 weeks off commonly reported
Which diluent and storage period should this material use?
FDA distinguishes ipamorelin free base from acetate and notes limited free-base water solubility and sensitivity to formulation conditions. The 10 mg/2 mL arithmetic is not verified solubility for every form.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeInt J Colorectal Dis, 2014: Postoperative ileus trial
- Clinical / regulatory / evidence landscapePharm Res, 1999: Human IV pharmacokinetics
- Clinical / regulatory / evidence landscapeFDA safety-risk resource: Evidence landscape
- Regulator assessmentFDA ipamorelin assessment (2024)
- Community/vendor report — unvalidatedVendor dissolution/gelling report
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.